ESC Congress 2022 (Photo by Kyle LaHucik)

#ESC22: 89bio heads to­ward PhI­II in se­vere hy­per­triglyc­eridemia, a field left be­hind by Pfiz­er ear­li­er this year 

BARCELONA — Two months af­ter re­veal­ing the topline da­ta — and quick­ly go­ing to the mar­ket for a cap­i­tal in­fu­sion of $95 mil­lion — 89bio is now pre­sent­ing the mid-stage re­sults of its high-triglyc­eride drug at the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy Con­gress.

In pa­tients with se­vere hy­per­triglyc­eridemia (SHTG) — in which triglyc­eride lev­els are more than three times what they should be and can lead to car­dio­vas­cu­lar dis­ease — 89bio’s drug per­formed bet­ter than place­bo. The FGF21 ana­log, named pe­gozafer­min, will en­ter a Phase III tri­al in the first half of next year, and da­ta from a Phase IIb in pa­tients with NASH, which re­cent­ly com­plet­ed en­roll­ment, is slat­ed for ear­ly next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.